Clean Science & Technology Ltd

- No new fundraising through debt or equity is planned currently. - All ongoing and planned CAPEX (~Rs. 300 crores through Clean Fino-Chem subsidiary and additional Rs. 170-180 crores for new products) will be fully funded through internal accruals. - The company has about Rs. 250 crores in cash on the balance sheet to support CAPEX requirements. - Management emphasized reliance on internal accruals for financing expansions and new projects without the need for external funding.

- Ongoing CAPEX of approximately Rs. 300 crores at Clean Fino-Chem Limited (CFCL), expected to commission by Q4 FY24, fully funded through internal accruals. - New pilot facility at CFCL to commission within next 4 weeks to aid scale-up from lab to commercial production. - Additional Rs. 170-180 crores earmarked for new products, announcement expected in next 1-2 quarters. - Rs. 250 crores investment planned starting January for HALS plant, sales expected to grow thereafter. - All new CAPEX and expansions to be financed through internal accruals; company currently holds Rs. 250 crores cash. - Rs. 30 crores CAPEX dedicated to pharma intermediate plant expected to generate Rs. 100 crores revenue, part of overall Rs. 200 crores multiproduct investment block. - Emphasis on state-of-the-art automated facilities to boost return on assets and reduce time to market.

- The company targets HALS sales to reach 200 tons per month by March FY25, indicating strong volume growth in new products. - Non-flagship (new) products contributed 25% of revenues this quarter, expected to increase, driving diversification and growth. - EBITDA margins remain robust at around 42%, supported by better product mix and lower input costs. - PAT margins improved to 29.1% despite lower absolute PAT due to lower non-operating income. - CAPEX plans include investing Rs. 170-180 crores over the next 1-2 quarters to expand new product lines, funded by internal accruals with Rs. 250 crores cash on hand. - Volume growth and margin expansion expected as new products scale up, potentially improving overall profitability and EPS over the medium term. - Pricing pressures currently persist, but stabilization anticipated once China normalizes, impacting future earnings positively.

- Siddharth Sikchi mentioned that about 25% of the business in the quarter came from new products, including TBHQ and DCC, which have started gaining traction. - HALS products are also contributing, with monthly sales of around 40-50 tons and recent export orders from Europe, China, and Taiwan. - The company is evaluating a Rs. 200 crore block for pharma and agro intermediates, with Bhoomi Pujan done in October and expected commissioning in about 9 months. - No specific quantified data on total current or pending orderbook was disclosed. - The management is cautiously optimistic about order growth but highlighted ongoing destocking impacting immediate demand. - Plans to announce new products and evaluate opportunities continue as market conditions evolve.

- Target to increase HALS sales to 200 tons per month by March FY25, with new products from the series also expected to contribute significantly. - Non-flagship/new products now contribute 25% of revenues and expected to grow, gradually reducing flagship product revenue share. - Growth to be driven by volume increases from newer products, including TBHQ and DCC, which are seen as steady, non-cyclical demand products. - Internal accruals will finance new CAPEX, supported by cash reserves (~Rs. 250 crores). - Demand recovery expected to be gradual over the next 2-3 quarters, with volumes likely to improve from 2Q FY24 levels. - Company emphasizes diversification in products and geography which is aiding margin resilience despite volume/realization pressures. - Pricing likely to remain under pressure until China normalizes; market conditions and pricing trends will be clearer in coming quarters.